xml version="1.0" encoding="UTF-8"?        Document  

false0000859737  0000859737   2019-12-30 2019-12-30  

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

______________________  

FORM 8-K 

______________________

Current Report Pursuant 

to Section 13 or 15(d) of the 

Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported) December 30, 2019 

 ______________________

HOLOGIC, INC. 

(Exact Name of Registrant as Specified in Its Charter)  

______________________

Delaware 

(State or Other Jurisdiction of Incorporation) 

1-36214 04-2902449

(Commission File Number) (I.R.S. Employer Identification No.)

[DATA_TABLE_REMOVED]

-508 263-2900 

(Registrant’s Telephone Number, Including Area Code)  

(Former Name or Former Address, if Changed Since Last Report)

 ______________________

Securities registered or to be registered pursuant to Section 12(b) of the Act.

[DATA_TABLE_REMOVED]

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.01 Completion of Acquisition or Disposition of Assets 

On December 30, 2019, Hologic, Inc. (the “Company”) completed its previously announced sale of its Cynosure medical aesthetics business (the “Transaction”) pursuant to the Securities Purchase Agreement, dated November 20, 2019, by and among the Company, Hologic Holdings Limited, a wholly owned subsidiary of the Company, and Lotus Buyer, Inc., a Delaware corporation and an affiliate of a fund managed by affiliates of Clayton Dubilier & Rice, LLC (“Purchaser”). After estimated closing adjustments, Hologic received net cash proceeds of approximately $142 million. The purchase price remains subject to adjustment upon finalization pursuant to the terms of the Securities Purchase Agreement.

Item 7.01 Regulation FD Disclosure 

On December 30, 2019, the Company issued a press release announcing the completion of the Transaction. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated into this Item 7.01 by reference. 

The information furnished in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(b) Pro Forma Financial Information

The following unaudited pro forma condensed combined financial information related to the Disposition is attached as Exhibit 99.2 hereto and is incorporated by reference herein: 

(i) Unaudited Pro Forma Condensed Consolidated Balance Sheet as of September 28, 2019. 

(ii) Unaudited Pro Forma Condensed Consolidated Statement of Income for the Year Ended September 28, 2019.

(d) Exhibits

[DATA_TABLE_REMOVED]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 

[DATA_TABLE_REMOVED]